Greg Pyszczymuka - 20 Feb 2025 Form 4 Insider Report for Evoke Pharma Inc (EVOK)

Role
Director
Signature
/s/ Matthew J. D'Onofrio, Attorney-in-fact for Greg Pyszczymuka
Issuer symbol
EVOK
Transactions as of
20 Feb 2025
Net transactions value
$0
Form type
4
Filing time
24 Feb 2025, 17:03:16 UTC
Previous filing
02 Jan 2025
Next filing
31 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVOK Stock Option (Right to Buy) Award $0 +5,833 $0.000000 5,833 20 Feb 2025 Common Stock 5,833 $5.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/3rd of the total number of shares of common stock subject to the option shall vest following each one-year period after February 20, 2025, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date, so that the option shall be fully vested on the third anniversary of the date of grant.